UK Secures Zero-Tariff US Pharmaceutical Deal with 25% Increase in NHS Medicine Investment
核心洞察
The UK becomes the only country worldwide to secure zero tariffs on pharmaceutical exports to the US for three years, protecting £11.1 billion in annual drug exports.
The NHS will increase medicine spending by 25% above current cost-effectiveness thresholds, marking the first significant investment increase in over two decades.
Bristol Myers Squibb (搜索) commits over $500 million in UK investment over five years, while the deal aims to reverse recent pharmaceutical divestments from major companies.
The UK has secured an unprecedented pharmaceutical trade agreement with the United States, becoming the only country worldwide to achieve zero tariffs on drug exports to the US market. The landmark deal protects £11.1 billion in annual pharmaceutical exports while committing the NHS to its first significant medicine investment increase in over two decades.
Under the three-year agreement, UK pharmaceutical shipments will remain exempt from US import taxes, safeguarding what represents 17.4% of all UK goods exports to America in the 12-month period ending September 2025. The US government had previously threatened tariff increases of up to 100% on branded drug imports, which constitute one of Britain's largest export categories to the US.
NHS Investment Surge Enables Advanced Therapies
In exchange for tariff protection, the UK government will increase NHS medicine spending by 25% above current cost-effectiveness thresholds. The agreement aims to boost overall NHS pharmaceutical expenditure from 0.3% to 0.6% of GDP over the next decade, enabling NICE to approve medicines that deliver significant health improvements even if previously declined on cost grounds.
The deal also reduces the rebate cap that pharmaceutical companies must pay back to the NHS from 20% to 15%, providing additional financial incentives for drug development and early launches in the UK market. Drug costs currently account for approximately 10% of the NHS health budget.
Science and Technology Secretary Liz Kendall emphasized the clinical impact: "This vital deal will ensure UK patients get the cutting-edge medicines they need sooner. Our world-leading UK firms continue to develop treatments that can change lives."
Reversing Pharmaceutical Investment Exodus
The agreement addresses mounting concerns over recent pharmaceutical divestments from the UK. While GSK announced a $30 billion investment in US research and manufacturing over five years, Merck (搜索) scrapped its planned £1 billion UK operations investment. AstraZeneca paused its £200 million Cambridge research facility investment, announcing instead a $50 billion US investment plan.
Bristol Myers Squibb (搜索) has already responded positively to the new deal, committing over $500 million in UK investment across research, development, and manufacturing over the next five years. Chief Executive Chris Boerner stated: "This agreement is a sign of progress and one that creates an environment conducive to our continued presence in the UK."
Strategic Positioning for Life Sciences Leadership
The deal supports the UK government's ambition to establish Britain as Europe's leading life sciences economy by 2030. The agreement includes mitigations under the US 'Most Favoured Nation' drug pricing initiative, allowing continued access to latest treatments and encouraging pharmaceutical companies to prioritize the UK for early medicine launches.
Health Minister Zubir Ahmed highlighted the patient benefits: "This deal is fundamentally about putting patients first – patients and families facing serious illness, this represents new hope and the possibility of treatments that could transform and even save lives."
The UK's track record includes breakthrough medicines such as Blenrep, a revolutionary blood cancer (搜索) therapy for multiple myeloma (搜索), where the NHS in England became the first health system globally to implement the treatment.
Business and Trade Secretary Peter Kyle noted the economic significance: "This deal guarantees that UK pharmaceutical exports – worth at least £5 billion a year – will enter the US tariff-free, protecting jobs, boosting investment and paving the way for the UK to become a global hub for life sciences."
William Bain, head of trade policy at the British Chambers of Commerce, added: "This deal will promote exports, boost investment and enhance UK competitiveness as a production and innovation base for world-leading medicines and treatments."